Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4932718 | 0.88 | L3MBTL1 (0.54) | MAPTPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL20569608 | 0.85 | KMT2A (0.58) | MAPTPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL102797 | 0.79 | ALDH1A1 (0.60) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3427781 | 0.79 | MAPT (0.72) | MAPTPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL3426210 | 0.79 | MAPT (0.72) | MAPTPOLBALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3141636 | 0.78 | ALDH1A1 (0.58) | MAPTPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL19461342 | 0.78 | POLB (0.46) | MAPTPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL10126582 | 0.78 | MAPT (0.70) | MAPTPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL3911494 | 0.78 | MAPT (0.70) | MAPTPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL4029063 | 0.78 | MAPT (0.70) | MAPTPOLBALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077729-A1 | New carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-04-22 | — | — | US | disclosed |
| WO-2004013115-A2 | CARBOXAMIDES, PRODUCTION AND USE THEREOF AS MEDICAMENTS____ | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-02-12 | — | — | WO | disclosed |
| EP-1360170-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-11-12 | — | — | EP | disclosed |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062748-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077729-A1 | New carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | F2, F11, F12 | MAPT 4082/4885POLB 3059/4885ALDH1A1 200/4885 |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | SERPINC1, TFPI, F2 | MAPT 4378/4885POLB 3255/4885ALDH1A1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.